Novo Nordisk Settles Allegations of Improperly Sourced Injection Needles, for $6.3 Million
Danish pharma company Novo Nordisk will pay $6.3 million to settle allegations that it sold hypodermic needles to the U.S.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.